Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Stanley Black & Decker, Inc. (SWK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Stanley Black & Decker, Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while Stanley Black & Decker, Inc. trades at $86.34 (market cap $13.89B). The key difference: Stanley Black & Decker, Inc. is far larger — about 3.1× ACADIA Pharmaceuticals Inc.'s market cap, and Stanley Black & Decker, Inc. pays a 3.71% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | SWK | |
|---|---|---|
Market Cap | $4.49B | $13.89B |
Sector | Health | — |
52-Week High | $28.06 | $94.12 |
52-Week Low | $20.06 | $62.12 |
Enterprise Value | $3.69B | $20.06B |
Dividend Yield | — | 3.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Stanley Black & Decker (SWK) trades at $89.37, down 2.75% today, with a bullish technical signal from moving averages but neutral oscillators. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 results pending. Revenue trends show stabilization around $15B annually, while net income improved to $401.9M in 2025. Debt reduction remains a priority, supported by positive operating cash flow of $971.2M.
SWK offers a turnaround story with improving profitability and shareholder returns via dividends, but faces headwinds from weak Tools & Outdoor demand and high debt levels. Analyst consensus is mixed with a $82.75 price target below current levels, suggesting cautious optimism amid execution risks and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →
